Abstract 5866: Statins Improve Survival in Patients with Severe Aortic Regurgitation
Background: Statins have beneficial biological effects on left ventricular myocardium, pulmonary vasculature and aortic valve degeneration. We explored if these effects translate into a clinical benefit in patients with severe aortic regurgitation.
Methods: Our echocardiographic database was screened for patients with severe AR from 1993 to 2007, yielding a total of 758 patients. Detailed chart reviews were performed for clinical, demographic and therapeutic data. Survival data was obtained from social security death index and was analyzed as a function of statin therapy.
Results: Of the 758 patients with severe AR, 152 were on a statin. Those on statins had a higher prevalence of coronary artery disease (CAD, 55% vs. 28%, p<0.0001), diabetes mellitus (21% vs. 12%, p0.004), hypertension (78% vs. 61%, p<0.0001) and male gender (66 vs. 58%, p=0.05) with similar age (both 61 years). Statin therapy was associated with a higher survival rate compared to those without (1 and 5 year survival rates 88% and 78% compared to 72% and 60% respectively, p=0.009). Using the Cox proportional hazards model, statin therapy remained an independent predictor of better survival (HR 0.577, 95% CI 0.387–0.859, p=0.007) after adjusting for age, gender, CAD, diabetes mellitus, aortic valve replacement, and use of aspirin use, beta-blockers or ACE inhibitors. The beneficial effect of statin was seen in those without CAD or diabetes.
Conclusions: Statin therapy is associated with an independent survival benefit in patients with severe AR. This finding warrants further studies.